The point of an extended suspension, page-54

Were just guessing at numbers here but it gives us something to do until the real action recommences. The notes to the September 4c disclose infusion revenue for the quarter of $3.2m. If we achieve that again for the final quarter in December (last year was $4.2m for the Dec qtr) then the full year revenue will be in the order of $14m/$15m. Using the six monthly numbers the profit was around 15% of revenue so the annual profit should be in the order of $2m. That would substantially increase Daz's valuation but also raise the question of whether we would want to sell the only profit making sector of the business.